Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epoprostenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR known ✓ | P43119 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | PPARD | Q03181 | 2/20 | 0.71 |
| ▸ | PPARA | Q07869 | 2/20 | 0.71 |
| ▸ | PPARG | P37231 | 1/20 | 0.71 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.56 |
| ▸ | PTGFR | P43088 | 2/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.56 |
| ▸ | SLCO2A1 | Q92959 | 1/20 | 0.56 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epoprostenol SCHEMBL16783375 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL16783374 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL22607961 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL24340812 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL705594 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL24033081 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL4165739 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL24612535 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL21283002 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL6227411 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3575791-B1 | BLOOD TREATMENT METHOD AND BLOOD COLLECTION TUBE | ARKRAY INC (JP) | 2024-01-10 | — | — | EP | disclosed |
| CN-110547288-B | Blood processing method and blood collection tube | 爱科来株式会社 | 2022-09-02 | — | — | CN | disclosed |
| CN-110547288-A | Blood processing method and blood collection tube | ARKRAY INC | 2019-12-10 | — | — | CN | disclosed |
| EP-3575791-A1 | BLOOD TREATMENT METHOD AND BLOOD COLLECTION TUBE | ARKRAY, Inc. (JP) | 2019-12-04 | — | — | EP | disclosed |
| EP-3195857-A1 | USE OF A TRP MODULATOR FOR THE PROPHYLAXIS AND/OR ALLEVIATING OF GRASS TETANY AND/OR PARTURIENT PARESIS IN TYLOPODA OR RUMINANTS | Freie Universität Berlin (DE) | 2017-07-26 | — | — | EP | disclosed |
| US-9693971-B2 | Compositions for alleviating gastrointestinal tract disorders or associated systemic disorders in ruminants and camelids | FREIE UNIVERSITÄT BERLIN (DE) | 2017-07-04 | — | — | US | disclosed |
| EP-2879662-B1 | COMPOSITION FOR ALLEVIATING GASTROINTESTINAL DEFECTS OR SYSTEMIC SYMPTOMES ASSOCIATED HEREWITH IN RUMINANTS AND CAMELIDS | FREIE UNIVERSITÄT BERLIN (DE) | 2017-02-08 | — | — | EP | disclosed |
| US-20150164822-A1 | COMPOSITIONS FOR ALLEVIATING GASTROINTESTINAL TRACT DISORDERS OR ASSOCIATED SYSTEMIC DISORDERS IN RUMINANTS AND CAMELIDS | PERFORMANAT GMBH (DE) | 2015-06-18 | — | — | US | disclosed |
| EP-2879662-A1 | COMPOSITIONS FOR ALLEVIATING GASTROINTESTINAL TRACT DISORDERS OR ASSOCIATED SYSTEMIC DISORDERS IN RUMINANTS AND CAMELIDS | Freie Universität Berlin (DE) | 2015-06-10 | — | — | EP | disclosed |
| WO-2014020067-A1 | COMPOSITIONS FOR ALLEVIATING GASTROINTESTINAL TRACT DISORDERS OR ASSOCIATED SYSTEMIC DISORDERS IN RUMINANTS AND CAMELIDS | FREIE UNIVERSITÄT BERLIN (DE) | 2014-02-06 | — | — | WO | disclosed |
| EP-1810693-A2 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | Shering Corporation (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006124713-A2 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONES | MICROBIA, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006122186-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006116499-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA | MICROBIA, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006102674-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006086562-A2 | PHENYLAZETIDINONE DERIVATIVES | MICROBIA, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| CN-1658903-A | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | SCHERING CORP (US) | 2005-08-24 | — | — | CN | disclosed |
| EP-1353694-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | Schering Corporation (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | SCHERING CORPORATION | 2002-10-10 | — | — | US | disclosed |
| WO-2002058734-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | APOB, FABP2, CYP46A1 | PTGIR 43/4885ALDH1A1 2630/4885MEN1 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.